NBRV Leaps On Study Data, CSII Takes A Hit, CLVS Abuzz, New Dimension For DMTX

The following are some of the biotech stocks that made their way onto the Day’s Gainers & Losers’ list of September 18, 2017.

GAINERS

1. Dimension Therapeutics Inc. (DMTX)

Gained 40.48% to close Monday’s (Sep.18) trading at $5.90.

News: The Company has received an acquisition proposal from Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx has proposed to acquire Dimension for $5.50 per share in cash to be effectuated via a tender offer.

On August 25, 2017, Dimension entered into a definitive merger agreement with REGENXBIO Inc, and it was supported by Dimension’s Board of Directors. As of this time, Dimension’s Board of Directors has not changed its recommendation in support of the merger with REGENXBIO.

Now that a new offer has come up, Dimension’s Board of Directors, in consultation with its independent legal and financial advisors, will carefully review and consider the Ultragenyx proposal.

2. Nabriva Therapeutics plc (NBRV)

Gained 29.30% to close Monday’s trading at $8.87.

News: The Company has reported positive top-line results from its phase III trial of Lefamulin (IV/oral) in patients with moderate to severe community acquired bacterial pneumonia.

In the trial, dubbed LEAP 1, Lefamulin (IV/oral) met all primary FDA and EMA endpoints with a favorable tolerability profile.

Related link

Keep An Eye On These Biotech Stocks This Month

3. GlycoMimetics Inc. (GLYC)

Gained 18.19% to close Monday’s trading at $13.97.

News: No news

Near-term catalysts:

— Anticipate announcing durability of response and overall survival from phase II study of GMI-1271 for treatment of adults with relapsed/refractory acute myeloid leukemia in Q4, 2017.
— A phase III trial of Rivipansel for the treatment of vaso-occlusive crisis of sickle cell diseases is expected to complete enrollment in the second half of 2018.

4. Quidel Corporation (QDEL)

Gained 14.24% to close Monday’s trading at $40.91.

News: The Company announced a revised Agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) Assay business run on Beckman Coulter Analyzers.

The revised agreement reflects Quidel’s direct commercial responsibility for all Beckman Coulter BNP sales globally, while the business arrangement for the pending acquisition of Alere’s Triage MeterPro assets is substantially unchanged.

Quidel will acquire the Triage business, including real estate for the San Diego Triage facilities, and the global BNP business for a total consideration of up to $680 million, comprised of the previously…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *